[Neurosarcoidosis: Diagnosis and therapeutic issues].

[1]  D. Galanaud,et al.  Spinal Koebner phenomenon: Medullar sarcoidosis facing a discal hernia. , 2017, Joint, bone, spine : revue du rhumatisme.

[2]  P. Validire,et al.  [Endobronchial ultrasonography (EBUS) for the internist]. , 2016, La Revue de medecine interne.

[3]  L. Vasconcellos,et al.  Isolated Central Nervous System Vasculitis as a Manifestation of Neurosarcoidosis. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[4]  M. Brouwer,et al.  Neurosarcoidosis in a Tertiary Referral Center , 2016, Medicine.

[5]  D. Maucort-Boulch,et al.  Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients , 2016, Journal of Neurology.

[6]  B. Weinshenker,et al.  Discriminating long myelitis of neuromyelitis optica from sarcoidosis , 2016, Annals of neurology.

[7]  J. Reny,et al.  [Abnormal neurological manifestations in a 44-year-old man]. , 2016, La Revue de medecine interne.

[8]  O. Ciccarelli,et al.  MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES , 2016, The Lancet Neurology.

[9]  D. Birnie,et al.  Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis , 2016, Heart.

[10]  C. Thongprayoon,et al.  Sarcoidosis and risk of venous thromboembolism: A systematic review and meta-analysis. , 2015, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[11]  A. Bhigjee,et al.  The use of cladribine in neurosarcoidosis: A report of two cases , 2015, Clinical neurology and neurosurgery (Dutch-Flemish ed. Print).

[12]  D. Courvoisier,et al.  Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis , 2015, Journal of Neuroimmunology.

[13]  J. Grutters,et al.  Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis , 2015, European Respiratory Journal.

[14]  G. Sobue,et al.  Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy , 2015, Journal of Neurology.

[15]  R. Gold,et al.  Sarcoid neuropathy: Correlation of nerve ultrasound, electrophysiological and clinical findings , 2014, Journal of the Neurological Sciences.

[16]  E. Kerty,et al.  Overnight Response to Infliximab in Neurosarcoidosis: A Case Report and Review of Infliximab Treatment Practice , 2014, Clinical neuropharmacology.

[17]  R. Baughman,et al.  Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. , 2014, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[18]  D. Haynes,et al.  Cranial Base Manifestations of Neurosarcoidosis: A Review of 305 Patients , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[19]  H. Wiendl,et al.  Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. , 2014, JAMA neurology.

[20]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[21]  A. Prasse,et al.  The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. , 2014, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[22]  F. Ducray,et al.  Progressive multifocal leukoencephalopathy in patients with sarcoidosis , 2014, Neurology.

[23]  J. Tavee,et al.  Spinal Cord Neurosarcoidosis , 2014, The American journal of the medical sciences.

[24]  K. Ruprecht,et al.  Neurosarcoidosis: Correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity , 2013, Journal of the Neurological Sciences.

[25]  P. Zanen,et al.  Methotrexate vs azathioprine in second-line therapy of sarcoidosis. , 2013, Chest.

[26]  J. Grutters,et al.  Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis , 2013, European Respiratory Journal.

[27]  D. Maucort-Boulch,et al.  Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. , 2013, QJM : monthly journal of the Association of Physicians.

[28]  M. Soussan,et al.  Functional Imaging in Extrapulmonary Sarcoidosis: FDG-PET/CT and MR Features , 2013, Clinical nuclear medicine.

[29]  S. Bartels,et al.  FDG PET findings leading to diagnosis of neurosarcoidosis , 2013, Clinical Neurology and Neurosurgery.

[30]  D. Collins,et al.  Neurosarcoidosis‐related intracranial haemorrhage: three new cases and a systematic review of the literature , 2013, European journal of neurology.

[31]  M. Judson,et al.  Isolated Neurosarcoidosis: Case Series in 2 Sarcoidosis Centers , 2012, The neurologist.

[32]  F. Cotton,et al.  Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. , 2012, QJM : monthly journal of the Association of Physicians.

[33]  M. Judson,et al.  Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. , 2012, Presse medicale.

[34]  J. Gascón-Bayarri,et al.  Neurosarcoidosis: report of 30 cases and a literature survey. , 2011, European journal of internal medicine.

[35]  H. Sasaki,et al.  Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients , 2011, Journal of Neurology.

[36]  S. Vukusic,et al.  Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy , 2011, Neurology.

[37]  E. Cho,et al.  Neurosarcoidosis presenting as an anterior horn syndrome , 2010, Journal of Neuroimmunology.

[38]  S. Pati,et al.  A CASE OF NEUROSARCOIDOSIS SUCCESSFULLY TREATED WITH RITUXIMAB , 2010, Neurology.

[39]  D. Galanaud,et al.  Spinal Cord Sarcoidosis: Clinical and Laboratory Profile and Outcome of 31 Patients in a Case-Control Study , 2010, Medicine.

[40]  R. Dengler,et al.  Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis , 2009, Journal of the Neurological Sciences.

[41]  陶仲为.  Sarcoidosis , 2009 .

[42]  G. Lauria,et al.  Intraepidermal nerve fiber density and its application in sarcoidosis , 2009, Neurology.

[43]  H. Moses,et al.  Presentations and outcomes of neurosarcoidosis: a study of 54 cases. , 2009, QJM : monthly journal of the Association of Physicians.

[44]  B. Segal,et al.  Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil , 2009, Neurology.

[45]  N. Scolding,et al.  Neurosarcoidosis: a study of 30 new cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[46]  S. Renowden,et al.  Treatment of refractory neurosarcoidosis with Infliximab , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[47]  G. Raghu,et al.  Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial , 2008, European Respiratory Journal.

[48]  M. Linskey,et al.  Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. , 2008, Surgical neurology.

[49]  G. Reach,et al.  Sarcoidosis: Clinical, Hormonal, and Magnetic Resonance Imaging (MRI) Manifestations of Hypothalamic-Pituitary Disease in 9 Patients and Review of the Literature , 2007, Medicine.

[50]  T. Scott,et al.  Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. , 2007, Archives of neurology.

[51]  L. Féasson,et al.  Granulomatous myositis: A clinical study of thirteen cases , 2007, Muscle & nerve.

[52]  P. Dyck,et al.  The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases , 2006, Journal of the Neurological Sciences.

[53]  P. Debré,et al.  The immune paradox of sarcoidosis and regulatory T cells , 2006, The Journal of experimental medicine.

[54]  A. Reginato,et al.  Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. , 2005, Seminars in arthritis and rheumatism.

[55]  N. Girard,et al.  Infections opportunistes et sarcoïdose , 2004 .

[56]  E. Hoitsma,et al.  Neurosarcoidosis: a clinical dilemma , 2004, The Lancet Neurology.

[57]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[58]  A. Destée,et al.  Long-term follow-up of neurosarcoidosis , 2001, Neurology.

[59]  R. Baughman,et al.  Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[60]  J. Piette,et al.  Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. , 2000, Radiology.

[61]  M. Rovaris,et al.  Central nervous system sarcoidosis--diagnosis and management. , 1999, QJM : monthly journal of the Association of Physicians.

[62]  O. Sharma.  Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. , 1998, Archives of neurology.

[63]  J. Broderick,et al.  Diagnosis and management of neurological sarcoidosis. , 1997, Archives of internal medicine.

[64]  O. Sharma,et al.  Neurosarcoidosis: a personal perspective based on the study of 37 patients. , 1997, Chest.

[65]  B. Stern,et al.  Therapeutic considerations in patients with refractory neurosarcoidosis. , 1995, Archives of neurology.

[66]  B. Stern,et al.  The treatment of neurosarcoidosis with cyclosporine. , 1992, Archives of neurology.

[67]  D. Laplane,et al.  Neurosarcoidosis: Signs, Course and Treatment in 35 Confirmed Cases , 1990 .

[68]  D. Griffin,et al.  Neurosarcoidosis , 1987, Neurology.

[69]  B. Stern,et al.  Neurosarcoidosis , 1987, Neurology.

[70]  F. Tanaka,et al.  Interleukin 10 Level in the Cerebrospinal Fluid as a Possible Biomarker for Lymphomatosis Cerebri. , 2015, Internal medicine.